Her2
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
Coverage of Her2 is accelerating : 7 signals on the latest tracked day, up 75% from its three-week baseline of 4, across 3 domains (unchanged from a week ago).
If Her2 matters to your work, the information environment around it is moving faster than its own baseline — worth a daily look while the build lasts.
What’s changed
- Real-world data on HER2-positive metastatic CRC from 14 Japanese centers · crc-digest · 2026-09-06
- Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy · The ASCO Post · 2026-09-04
- Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer · The ASCO Post · 2026-08-27
- Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial · Annals of Oncology · 2026-08-25
- FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer · The ASCO Post · 2026-08-25
- HER2-Targeted Regimen Yields High Pathologic Complete Response Rate in Locally Advanced Breast Cancer · The ASCO Post · 2026-08-24
What the reporting says
Across 64 tracked stories from 23 outlets, reporting on Her2 most often describes regulatory approvals (14), military action (1).
It shows up alongside Her2 Positive (25), Colorectal Cancer (32), Her2 Negative (19), Immunotherapy (17), Erbb2 (11), ASCO (15), Egfr (14), ctDNA (12).
Two steps out: Braf (through Colorectal Cancer, 32 shared stories on the weaker link); Chen (through Colorectal Cancer, 32 shared stories on the weaker link); KRAS (through Colorectal Cancer, 32 shared stories on the weaker link); MSI-H (through Colorectal Cancer, 32 shared stories on the weaker link).
Tracked since Mar 22, with coverage on 38 separate days — concentrated in Society News and Oncology.